UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000056567
Receipt number R000064646
Scientific Title A pilot study to confirm the effect of test foods on sleep quality
Date of disclosure of the study information 2025/01/11
Last modified on 2024/12/25 17:06:37

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A pilot study to confirm the effect of test foods on sleep quality

Acronym

A pilot study to confirm the effect of test foods on sleep quality

Scientific Title

A pilot study to confirm the effect of test foods on sleep quality

Scientific Title:Acronym

A pilot study to confirm the effect of test foods on sleep quality

Region

Japan


Condition

Condition

Healty volunteers

Classification by specialty

Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To examine whether the test foods affect the quality of sleep in women prone to PMS.
As a preliminary study, we will measure growth hormone levels in the blood, body composition, and skin tests to see if there is an effect on growth hormone, bone density, muscle mass, and skin condition.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

pittsburgh sleep quality index(PSQI)

Key secondary outcomes

Daily Record of Severity of Problems(DRSP)
Fatigue Visual Analog Scale
Body composition measurement
Skin condition
Fitbit Sleep Profiles
Blood growth hormone concentration


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Prevention

Type of intervention

Food

Interventions/Control_1

Oral intake of test food for 4 weeks

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

55 years-old >

Gender

Female

Key inclusion criteria

1) Japanese women aged 20 to 55
2) Those who have problems with sleep quality
3) Those with a regular menstrual cycle (25-38 days)
4) Those who have a tendency towards premenstrual syndrome
5) Healthy individuals who are not undergoing treatment for any illness or taking any medication
6) Those who voluntarily wish to participate in the clinical trial and can provide written informed consent
7)Those who can maintain a consistent daily lifestyle during the test period

Key exclusion criteria

1) Those who have been taking medicines regularly within the last 3 months prior to the start of the study (excluding temporary medications such as painkillers and cold medicines)
2) Those with serious illnesses (diabetes, heart disease, liver disease, kidney disease, cancer, etc.) or mental illnesses
3) Those with a history of serious illness (diabetes, heart disease, liver disease, kidney disease, cancer, etc.) or digestive system disease
4) Those who have regularly taken specific health foods, functional foods, health foods (including supplements), etc., that may affect the study, at least three times a week within three months prior to the start of the study.
5) Those who cannot stop taking foods for specified health uses, foods with functional claims, health foods (including supplements), etc. that may affect the study during the study period.
6) Those whose menstruation has stopped completely
7) Those who are pregnant or breastfeeding, or who plan to or wish to do so during the study period
8) Those who live in an environment where sleep is disturbed by factors other than themselves, such as living with infants or people who require care
9) Those who drink a lot of alcohol (40g or more of pure alcohol per day on average)
10) Those with extremely irregular eating habits or those with irregular lifestyles such as working night shifts
11) Those with drug or food allergies
12) Participants in clinical trials related to sleep quality or PMS within 6 months of the start of the study
13) Those who are currently participating in another clinical trial, have completed a clinical trial within the last 4 weeks, or are scheduled to participate in another clinical trial while participating in this study.
14) Those who are deemed ineligible to participate in this study by the investigator

Target sample size

15


Research contact person

Name of lead principal investigator

1st name Tadashi
Middle name
Last name Watanabe

Organization

Watanabe Hospital

Division name

chairperson

Zip code

144-0043

Address

1-5-16, Haneda, Ota-ku, Tokyo, Japan

TEL

03-3741-0223

Email

wnb.cto@gmail.com


Public contact

Name of contact person

1st name Tatsuo
Middle name
Last name Uetake

Organization

CXwellness, Inc.

Division name

Representative Directo

Zip code

173-0004

Address

2-63-9-401 Itabashi, Itabashi-ku, Tokyo JAPAN

TEL

03-6915-5507

Homepage URL


Email

uetake@cx-wellness.com


Sponsor or person

Institute

MITSUBISHI GAS CHEMICAL COMPANY, INC.

Institute

Department

Personal name



Funding Source

Organization

MITSUBISHI GAS CHEMICAL COMPANY, INC.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Ethics Review Committee of Watanabe Hospital

Address

1-5-16, Haneda, Ota-ku, Tokyo, JAPAN

Tel

03-3741-0223

Email

wnb@cto-net.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2025 Year 01 Month 11 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2024 Year 01 Month 11 Day

Date of IRB

2024 Year 12 Month 25 Day

Anticipated trial start date

2025 Year 01 Month 12 Day

Last follow-up date

2025 Year 06 Month 30 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2024 Year 12 Month 25 Day

Last modified on

2024 Year 12 Month 25 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000064646